| VF | 1) Ventricular Fibrillation ? Tx of Ventricular Fibrillation ... |
|---|---|
| WPW Syndrome | Wolff-Parkinson-White Syndrome ? CIx 1. Drugs; AV Conduct... |
| BL | Barre-Lieou [syndrome]; basal lamina; baseline; Bessey-Lowry [unit]; black light; bladder; bleeding;... |
| BLE | both lower extremities; buffered lidocaine with epinephrine |
| LANE | lidocaine, atropine, naloxone, epinephrine [drugs that may be administered via endotracheal tube] |
| DBcyclic AMP | Dibutyryl cyclic AMP |
|---|---|
| L | Lidocaine |
| LID | Lidocaine |
| xylocaine | Lidocaine |
| lidocaine | Lignocaine |
oral (경구, 입의, 경구의, 구강, 구강의
| lidocaine | <cardiology, drug> A local anaesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of procaine but its duration of action is shorter than that of bupivacaine or prilocaine. Pharmacological action: anaesthetics, local, anti-arrhythmia agents. Decreases automaticity, depresses conduction in reentrant pathways and may raise fibrillation threshold, especially in combination with bretylium. Uses: The drug of first choice for ventricular arrhythmias, ventricular ectopy, and wide complex tachycardias of unknown origin. Dose: 1-1.5 mg/kg IV bolus, followed by additional 0.5-1.5 mg/kg every 5-10 min to a total of 3 mg/kg. Can be administered via the endotracheal tube. Use 2 to 2.5 times the intravenous dose. Upon return of circulation, use continuous infusion at 2 - 4 mg/min. Reduce the maintenance dose if decreased cardiac output or hepatic failure or more than 70 years of age. Potential complications: dizziness, drowsiness, disorientation, seizures, hypotension - causes vasodilation; myocardial depression at higher concentrations; heart block - only rarely seen with high levels. Chemical name: 2-(diethylamino)-N-(2,6-dimethylphenyl)-acetamide (15 Mar 2000) |
|---|---|
| lidocaine N-deethylase | <enzyme> Catalyzed mainly by cytochrome p-450 3a2 in rat liver microsomes Registry number: EC 1.- (26 Jun 1999) |
| AMP | <abbreviation> Adenosine monophosphate; specifically, the 5'-monophosphate unless modified by a numerical prefix. See: adenylic acid. (05 Mar 2000) |
| AMP-activated protein kinase kinase | <enzyme> An endogenous kinase kinase; reactivates the inactive form of AMP-activated protein kinase (AMP-pk); phosphorylates the 63-kD subunit of AMP-pk Registry number: EC 2.7.1.- Synonym: AMP-pk reactivator, hmg CoA reductase kinase kinase (26 Jun 1999) |
| AMP deaminase | <enzyme> An enzyme that catalyses the deamination of AMP to imp. Chemical name: AMP aminohydrolase Registry number: EC 3.5.4.6 (12 Dec 1998) |
| receptors, cyclic AMP | Cell surface proteins that bind cyclic AMP with high affinity and trigger intracellular changes which influence the behaviour of cells. The best characterised cyclic AMP receptors are those of the slime mold dictyostelium discoideum. The transcription regulator cyclic AMP receptor protein of prokaryotes is not included nor are the eukaryotic cytoplasmic cyclic AMP receptor proteins which are the regulatory subunits of cyclic AMP-dependent protein kinases. (12 Dec 1998) |
| polyphosphate AMP phosphotransferase | <enzyme> From acinetobacter; catalyses (polyphosphate)n and AMP to (polyphosphate)n-1 and ADP Registry number: EC 2.7.4.- Synonym: pamp phosphotransferase (26 Jun 1999) |
| cyclic AMP | <molecular biology> 3'5' cyclic ester of AMP. The first second messenger hormone signalling system to be characterised. Generated from ATP by the action of adenyl cyclase that is coupled to hormone receptors by G-proteins (GTP-binding proteins). CAMP activates a specific (cAMP dependent) protein kinase and is inactivated by phosphodiesterase action giving 5'AMP. Also functions as an extracellular morphogen for some slime moulds. (18 Nov 1997) |
| cyclic AMP-dependent protein kinase | Enzymes which attach phosphate groups to the serine or tyrosine amino acids on proteins as a means of regulating the proteins' activity in metabolic reactions. (09 Oct 1997) |
| cyclic AMP-dependent protein kinases | <enzyme> A group of enzymes that are dependent on cyclic AMP and catalyze the phosphorylation of serine or threonine residues on proteins. Registry number: EC 2.7.10.- (12 Dec 1998) |
| cyclic AMP receptor protein | A transcriptional regulator in prokaryotes which, when activated by binding cyclic AMP, acts at several promoters. Cyclic AMP receptor protein was originally identified as a catabolite gene activator protein. It was subsequently shown to regulate several functions unrelated to catabolism, and to be both a negative and a positive regulator of transcription. Cell surface cyclic AMP receptors are not included (cyclic AMP receptors), nor are the eukaryotic cytoplasmic cyclic AMP receptor proteins, which are the regulatory subunits of cyclic AMP-dependent protein kinases. (12 Dec 1998) |
| dibutyryl cyclic AMP | An analogue of cyclic AMP that shares some of the pharmacological effects of this nucleotide, but is generally believed to enter cells more readily on account of its greater hydrophobicity. (18 Nov 1997) |
| DNA-binding protein, cyclic AMP-responsive | A protein that has been shown to function as a calcium regulated transcription factor as well as a substrate for depolarisation-activated calcium calmodulin-dependent protein kinases I and II. This protein functions to integrate both calcium and camp signals. (12 Dec 1998) |
| 2,3-dihydroxybenzoate-AMP ligase | <enzyme> Catalyses the conversion of 2,3-dihydroxybenzoate and ATP to form (2,3-dihydroxybenzoyl)adenylate, this acyladenylate remains bound to the enzyme for further reactions in the overall biosynthesis of enterobactin Registry number: EC 6.5.- Synonym: 2,3dhb-AMP ligase, ente gene product (26 Jun 1999) |
| 3',5'-cyclic AMP synthetase | <enzyme> Enzyme responsible for the ATP. (06 May 1997) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|---|---|---|---|
|
휴온스염산리도카인주사1.8ml - 새창
|
휴온스 |
A29500411 | Lidocaine Hydrochloride | 전문의약품 | 급여 | 분업예외의약품 |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|